TRCT
AUTL

Tower Research Capital (TRC)’s Autolus Therapeutics AUTL Stock Holding History

Tower Research Capital (TRC)’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1K Sell
7,533
-12,984
-63% -$20.4K ﹤0.01% 3918
2026
Q1 		$28.3K Buy
20,517
+12,068
+143% +$18.3K ﹤0.01% 3225
2025
Q4 		$16.8K Sell
8,449
-1,819
-18% -$2.79K ﹤0.01% 3234
2025
Q3 		$16.7K Buy
10,268
+5,991
+140% +$11.7K ﹤0.01% 3461
2025
Q2 		$9.75K Sell
4,277
-1,580
-27% -$2.61K ﹤0.01% 3981
2025
Q1 		$9.08K Buy
5,857
+1,127
+24% +$2.29K ﹤0.01% 3823
2024
Q4 		$11.1K Buy
4,730
+1,790
+61% +$6.05K ﹤0.01% 3748
2024
Q3 		$10.7K Sell
2,940
-10,397
-78% -$41.5K ﹤0.01% 3728
2024
Q2 		$46.4K Buy
13,337
+11,721
+725% +$50.6K ﹤0.01% 3164
2024
Q1 		$10.3K Sell
1,616
-8,177
-83% -$51K ﹤0.01% 3714
2023
Q4 		$63.1K Sell
9,793
-7,903
-45% -$30.1K ﹤0.01% 2976
2023
Q3 		$41.2K Sell
17,696
-7,680
-30% -$21.9K ﹤0.01% 2708
2023
Q2 		$60.4K Sell
25,376
-4,352
-15% -$10.3K ﹤0.01% 2446
2023
Q1 		$55K Buy
29,728
+10,603
+55% +$20.7K ﹤0.01% 2395
2022
Q4 		$36K Buy
19,125
+12,618
+194% +$31.9K ﹤0.01% 2576
2022
Q3 		$14K Buy
6,507
+3,053
+88% +$9.04K ﹤0.01% 4204
2022
Q2 		$10K Buy
3,454
+480
+16% +$1.46K ﹤0.01% 4427
2022
Q1 		$13K Sell
2,974
-1,426
-32% -$6K ﹤0.01% 3955
2021
Q4 		$23K Sell
4,400
-1,648
-27% -$9.89K ﹤0.01% 3498
2021
Q3 		$40K Buy
6,048
+3,462
+134% +$21.9K ﹤0.01% 3124
2021
Q2 		$17K Sell
2,586
-494
-16% -$3.07K ﹤0.01% 4026
2021
Q1 		$17K Buy
3,080
+1,468
+91% +$10.9K ﹤0.01% 3992
2020
Q4 		$14K Sell
1,612
-3,591
-69% -$38.3K ﹤0.01% 4087
2020
Q3 		$61K Buy
5,203
+4,313
+485% +$62.5K ﹤0.01% 3449
2020
Q2 		$14K Buy
890
+259
+41% +$2.87K ﹤0.01% 3858
2020
Q1 		$4K Sell
631
-1,596
-72% -$14.8K ﹤0.01% 2342
2019
Q4 		$29K Buy
+2,227
New +$29.2K ﹤0.01% 1670
2019
Q2 		– Sell
-3,041
Closed -$96K – 3653
2019
Q1 		$96K Buy
+3,041
New +$86.5K 0.01% 1441
2018
Q4 		– Sell
-68
Closed -$2K – 3809
2018
Q3 		$2K Buy
+68
New +$1.84K ﹤0.01% 3405

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Tower Research Capital (TRC)'s AUTL Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Autolus Therapeutics (AUTL) stake by 63% in Q2 2026, selling an estimated $20.4K and leaving 7,533 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3918.

Tower Research Capital (TRC) first reported a position in AUTL in Q3 2018 and has held it in 29 quarters since. The position peaked at $96K in Q1 2019. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Tower Research Capital (TRC) held 7,533 shares of Autolus Therapeutics worth $12.1K as of Q2 2026.
  • Tower Research Capital (TRC) sold 12,984 Autolus Therapeutics shares in Q2 2026, an estimated $20.4K.
  • Autolus Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3918 holding.
  • Tower Research Capital (TRC) first reported a position in Autolus Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Autolus Therapeutics position peaked at $96K in Q1 2019.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.